Connect with us


Two IPO Stocks To Buy Or Sell This Month?

Joe Samuel




These Two Ride Sharing Stocks Have Slid But Does That Mean It’s An Opportunity Or Another Red Flag?

Earlier this year, Wall Street and the rest of the world was abuzz at the prospect of two of the most eagerly anticipated initial public offerings. Both belonged to ride-sharing companies. One was LYFT Inc (NASDAQ:LYFT) and the other was the global behemoth Uber Technologies Inc (NYSE:UBER).

IPO Stocks Hitting New Lows; Why?

The stocks didn’t perform that well, post-listing day and earlier this week, both stocks sunk to their record lows. The plunge took place last week. According to analysts, the decline is due to widespread skepticism about the business models of the companies. Over the past few weeks, many public companies have been subject to scathing criticism from the public.

[Read More] Top Biotechnology Stocks To Watch After Latest News

Last week, Uber stock dropped by as much as 4% to and hit a low of $28.15. This was the lowest level in its history. Lyft, which had its IPO ahead of Uber, saw its stock go down by 4% to hit $37.92. Uber had hit a previous low of $30.29, while the same for Lyft was $40.84.

Both of those lows had been reached in the last days of September. Uber’s valuation sits at $49 billion as opposed to its private valuation of $76 billion. The situation with Lyft is not as bad since it is current valuation stands at $11.6 billion as opposed to the private valuation of $15 billion.

What Does The Future Hold?

The current situation with many of the tech companies which had its IPOs this year is due to the increased scrutiny about the business models of these outfits. The final nail for investors had been the whole fiasco surrounding the IPO of the co-working space firm WeWork.

[Read More] 3 Tech Stocks To Watch That Released Big News This Month

The company has eventually decided against going for the IPO after it appeared that it would have to reduce its valuation from $45 billion to $15 billion. That gave rise to increased scrutiny of another tech IPOs as well and it seems it is a downturn that is going to take some time to reverse.

Continue Reading
Click to comment


Streaming Wars and the Future of Companies Involved

Joe Samuel



The much anticipated ‘streaming wars’ finally kicked off in November with the launch of Apple Inc. (NASDAQ:AAPL) TV+ and Walt Disney Co (NYSE:DIS) Plus. Considering the fact that two of the most cash-rich companies have entered the fray, it is now almost certain that there is going to be a prolonged tussle for market share. Moreover, many other streaming services are going to launch over the coming months. One of those is HBO Max, while another is Peacock by Comcast.

Key Analysis

streaming wars stocks to buy

The emergence of Netflix truly reflected the shift that was happening in the entertainment business and as more and more people moved from cable to streaming, it became clear that it was here to stay. Hence, it is no surprise that some of the giant corporations have now introduced their streaming services. While skeptics might say that customers might not go for so many services a month, research suggests that most customers will be willing to pay for 5 to 6 such services a month.

Netflix has captured 160 million customers and it is so entrenched that it is unlikely that it will lose many customers. On the other hand, Disney Plus has started off impressively and has garnered as many as 10 million signups since it launched November 12.

Read More

While the number of streaming services is rising, customers have also grown accustomed to a certain level of programming and hence, there are legitimate concerns over whether the number of shows can keep rising. Despite the spiraling rise in production budgets, producers in the United States are still producing in excess of 100 shows a year. Hence, the shortage of shows would not be a problem.

Content Reigns Supreme

It cannot be denied that production budgets are going to go through the roof for most of these companies, however, they are trying to earn through their streaming services in other ways.

movie stocks

Amazon offers its Prime free shipping services and other services to customers. On the other, Apple is making a concerted effort to sell more devices by way of its streaming services. Other niche streaming services are in the pipeline as well but analysts believe that the biggest pressure will be felt by cable companies. Cord-cutting has reached unprecedented levels over the past few years and it could rise further as the streaming wars gather pace in the upcoming quarters.

Continue Reading


PharmaCyte Biotech (PMCB) Successfully Completes Final Manufacturing Run of Clinical Trial Product

Jon Phillip



stock price news


PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova Singapore (Austrianova), has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.” The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration (FDA) to support PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer (LAPC).

The capsules, which are fully filled with genetically modified live cells, were immediately put into PharmaCyte’s clinical trial syringes and then frozen. Austrianova has shipped a representative sample of the frozen syringes to third-party laboratories in Europe to undergo “release testing” related to the “safety” of the product. Austrianova will conduct “release testing” in-house related to the “functionality” of the encapsulated cells.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “Today is a great day at PharmaCyte. We have cleared what was a major hurdle for us and have completed our most impactful milestone to date. Successfully completing two manufacturing runs is a milestone that has now been met as we progress toward our submission of an IND to the FDA so we can begin our clinical trial in LAPC.

“Our GMP consultant, cGMP Validation, has informed us that while two successful manufacturing runs are not required by the FDA to request a Phase 2b clinical trial, it could go a long way in demonstrating to the FDA that our manufacturing process is robust and reproducible – manufacturing qualities that are highly embraced by the FDA.”

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at:

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is developing the use of genetically modified liver cells and stem cells, as well as beta islet cells, to treat diabetes. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte, including statements regarding the timing and commencement of our first Phase 2b clinical trial. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise

More information about PharmaCyte can be found at Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

View source version on

Dr. Gerald W. Crabtree
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading


Liberty (SCAN.V) (LDDFF) Announces Private Placement of Units

Joe Samuel



penny stocks news

VANCOUVER and ATLANTA , Nov. 7, 2019 /CNW/ – Liberty Defense Holdings Ltd. (“Liberty”) (TSXV: SCAN, FRANKFURT : LD2, OTCQB: LDDFF), a leading concealed weapons detection company, is pleased to announce that it has arranged a non-brokered private placement of up to 10,870,000 units (“Units”) at a price of C$0.23 (the “Unit Price”) for aggregate gross proceeds of up to approximately C$2,500,000 (the “Offering”). Liberty will retain the option to increase the Offering to 15,217,000 Units for gross proceeds of up to approximately C$3,500,000 .

Each Unit will consist of one common share and one common share purchase warrant (a “Warrant”), with each whole Warrant entitling the holder to purchase one additional common share of the Company at a price of C$0.30 for 18 months following the closing of the Offering. The Warrants will be subject to an acceleration clause in the event the closing price of Liberty’s common shares is greater than C$0.45 for 10 consecutive trading days (the “Acceleration Event”). Liberty will give notice to the holders of the Acceleration Event and the Warrants will expire 30 days thereafter.

In connection with the Offering, Liberty has engaged Laurentian Bank Securities Inc. to act as its exclusive financial advisor for the Offering. The Company may pay finder’s fees in accordance with the policies of the TSX Venture Exchange in conjunction with the closing of the Offering.

The Company intends to use the net proceeds of the Offering to provide working capital and continue the advancement of HEXWAVE, specifically the targeted completion of the Alpha testing and the production of the initial Beta Units in Q1 2020.

All securities issued pursuant to the Offering will be subject to a statutory hold period expiring four months and one day from closing of the Offering. Completion of the Offering is subject to approval of the TSX Venture Exchange.

On Behalf of Liberty Defense
Bill Riker
CEO & Director

About Liberty Defense
Liberty provides security solutions for concealed weapon detection in high volume foot traffic areas and has secured an exclusive license from Massachusetts Institute of Technology ( MIT ), as well as a technology transfer agreement, for patents related to active 3D radar imaging technology that are packaged into the HEXWAVE product. The system is designed to provide discrete, modular and scalable protection to provide layered, stand-off detection capability. This is intended to provide a means to proactively counter evolving urban threats. The sensors with active 3D radar imaging and Artificial Intelligence (AI)-enhanced automatic detection are designed to detect metallic and non-metallic firearms, knives, explosives and other threats. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions. Learn more:


When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of their respective officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because the parties can give no assurance that such statements will prove to be correct. The forward-looking statements and information in this press release include, amongst others, information relating to completion of the Offering, the use of proceeds of the Offering, the completion of the Alpha testing of HEXWAVE and production of the initial Beta Units in Q1 2020, and the functionality of HEXWAVE. Such statements and information reflect the current view of Liberty. There are risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. There are a number of important factors that could cause Liberty’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others: the failure of Liberty to find suitable purchasers for the Offering; the failure of Liberty to obtain approval of the TSX Venture Exchange of the Offering, management’s discretion as to the use of proceeds of the Offering; currency fluctuations; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses; and general developmenty, market and industry conditions. The parties undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of their securities or their respective financial or operating results (as applicable).

Liberty cautions that the foregoing list of material factors is not exhaustive. When relying on Liberty’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Liberty has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of Liberty as of the date of this press release and, accordingly, are subject to change after such date. Liberty does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Liberty Defense Holdings Ltd.

View original content to download multimedia:

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid $75,000 (CASH) by Liberty Defense Holdings AND HAVE EXTENDED coverage for a period from 11/1/2019 – 11/30/2019. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!

Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (


Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact